MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: other"

  • 2017 International Congress

    Epidemiological profile and challenges of a reference public center for the treatment of neurological conditions using botulinum toxin type A: experience of a North-eastern center in Brazil.

    R. Prado, W. Cunha, P. Macêdo, A. Santiago, R. Sá, J. Santos, M. Machado (Aracaju, Brazil)

    Objective: To identify the epidemiological profile of patients treated with botulinum toxin type A (BTA) in a tertiary clinic in Brazil. Background: BTA is used to…
  • 2017 International Congress

    Palmaris Brevis Spasm:A rare cause of paediatric movement disorder

    T. Yeo, A. Yacoob (Singapore, Singapore)

    Objective: Case report of paediatric Palmaris Brevis Spasm (PBS) Background: PBS is a rare movement disorder causing intermittent twitching of the palmaris brevis muscle. This muscle…
  • 2017 International Congress

    Saliva changes and the oral health in Parkinson´s disease

    J. Tiigimäe-Saar, T. Tamme, P. Taba (Tartu, Estonia)

    Objective: The aim of this study was to determine the risk of change in the oral microflora and oral health in PD patients. Background: Parkinson…
  • 2017 International Congress

    A double-blind, randomized, placebo controlled study of botulinum toxin type A for limb pain in advanced Parkinson’s disease

    V. Bruno, M. Freitas, D. Mancini, J. Liu, J. Miyasaki, S. Fox (CABA, Argentina)

    Objective: To evaluate safety, tolerability and efficacy of botulinum toxin type A for limb pain in advanced Parkinson´s disease (PD). Background: Pain is a frequent…
  • 2017 International Congress

    Clinical features and response to botulinum toxin in primary and secondary hemifacial spasm

    S. Pandey, S. Jain (New Delhi, India)

    Objective: To study demographic and clinical features of  primary and secondary hemifacial spasm and assess their response to botulinum toxin therapy. Background: Hemifacial spasm (HFS)…
  • 2017 International Congress

    Botulinum Neurotoxin (BoNT) for treatment of functional (psychogenic) jerky movement disorders: a randomized placebo-controlled clinical trial

    Y. Dreissen, J. Dijk, J. Gelauff, E. Zoons, M. Contarino, R. Zutt, B. Post, D. van Poppelen, A. Munts, J. Speelman, R. de Haan, J. Koelman, M. Tijssen (Amsterdam, Netherlands)

    Objective: To assess the effectiveness of botulinum neurotoxin (BonT) in patients with functional jerky movement disorders Background: At least 2–9% of patients seen in movement…
  • 2017 International Congress

    Unusual facial synkinesia after Bell’s palsy: interactive Marin-Amat syndrome proven by surface electromyogram, successfully treated with low dose botulinum toxin A.

    H. Mori (Kurashiki, Japan)

    Objective: To clarify unusal facial synkinesia by using surface electromyogram and botulinum toxin A. Background: Marin-Amat syndrome is a facial synkinesis manifesting as involuntary eyelid…
  • 2017 International Congress

    Ultrasonography-guided Botulinum Toxin Type-A Injection in Tremor. An open-label Study

    H. Shehata, N. Shalaby, M. Basheer, A. Elmazny, S. Eljaafary (Cairo, Egypt)

    Objective: To assess the role of ultrasound-guided (US) Onabotulinumtoxin-A (BoNT-A) injections for various types of hand and head tremor. Background: Focal treatment of head and…
  • 2017 International Congress

    Diaphragmatic myoclonus successfully treated with Botulinum toxin A

    Y. He, B. Li, Y. Pan, X. Zhang, L. Jin (Shanghai, China)

    Objective: To report a rare case of diaphragmatic myoclonus, which would be the first case successfully treated by injecting Botulinum toxin A (BTX) into the diaphragm under…
  • 2017 International Congress

    Long-term effect of botulinum toxin injection in the external oblique muscle to treat camptocormia in three patients with Parkinson’s disease.

    H. Todo (Sanda, Japan)

    Objective: To examine long-term effect of botulinum toxin injection (BTX) in the external oblique muscle (EO) for camptocormia associated with Parkinson’s disease (PD). Background: Camptocormia…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley